Evaluation of the effect of Allopurinol on the frequency of ventricular and supraventricular arrhythmias

Evaluation of the effect of Allopurinol on the frequency of ventricular and supraventricular arrhythmias in patients with an implantable cardioverter-defibrillator

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120520009801N12

Enrollment

134

Registered

2024-02-19

Start date

2024-04-02

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Ventricular arrhythmias. Condition 2: Supraventricular arrhythmia. Re-entry ventricular arrhythmia Supraventricular tachycardia

Interventions

Intervention 1: Intervention group: Allopurinol 300 mg tablets, Hakim Pharmaceuticals, once a day for three months (67 people). Intervention 2: Control group: Placebo tablets made by the School of Pha

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age more than 18 years and less than 70 years Having an implantable cardioverter-defibrillator for more than 3 months before starting participation in the clinical trial Obtain informed consent from the patient

Exclusion criteria

Exclusion criteria: Taking the drug allopurinol before Moderate to severe kidney dysfunction (GFR < 60 ml/min/1.73m2) Significant impairment of liver function (Child-Pugh class B or C) Previous history of severe skin reactions like Steven Johnson Pregnancy or suspected pregnancy Active inflammation or infection Suffering from autoimmune diseases and malignancies Taking class I and III antiarrhythmic drugs Performing major surgeries Taking any medication with anti-inflammatory effect

Design outcomes

Primary

Measure	Time frame
Frequency of ventricular arrhythmias. Timepoint: The beginning of the study and 3 months later. Method of measurement: Examining the data obtained from the implantable cardiac defibrillator device.;Frequency of supraventricular arrhythmias. Timepoint: The beginning of the study and 3 months later. Method of measurement: Examining the data obtained from the implantable cardiac defibrillator device.	—

Measure

Time frame

Frequency of ventricular arrhythmias. Timepoint: The beginning of the study and 3 months later. Method of measurement: Examining the data obtained from the implantable cardiac defibrillator device.;Frequency of supraventricular arrhythmias. Timepoint: The beginning of the study and 3 months later. Method of measurement: Examining the data obtained from the implantable cardiac defibrillator device.

—

Secondary

Measure	Time frame
Uric acid level. Timepoint: Before the intervention and after 3 months. Method of measurement: Biochemistry test of the patient's blood sample.;Blood pressure. Timepoint: Before the intervention and after 3 months. Method of measurement: sphygmomanometer.;Hospitalization. Timepoint: Before the intervention and after 3 months. Method of measurement: Pulse oximeter device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Hooshang Mohammadpour

Mashhad University of Medical Sciences

mohamadpoorah@mums.ac.ir+98 51 1882 3255

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026